Search | Page 8 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies

    ... myelodysplastic syndromes (MDS) Associated Drug(s):  ... institutional criteria. Any second or subsequent CR. Secondary AML with prior malignancy that has been in remission for at least 12 ...

    Clinical Trial last updated 06/03/2016 - 2:37pm.

  2. A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib

    ... myelodysplastic syndromes (MDS) Phase:  ... but potential risk for adverse events in nursing infants secondary to treatment of the mother with ruxolitinib, breastfeeding should be ...

    Clinical Trial last updated 06/06/2016 - 2:32pm.

  3. Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

    ... in attacking cancer cells in patients with leukemia, MDS, lymphoma, Hodgkin disease, or MM, after they have received an ... or are not in a complete response at day 28 can receive secondary therapy. Drug: Methylprednisolone 1.6 mg/kg per day by vein ...

    Clinical Trial last updated 06/06/2016 - 12:41pm.

  4. Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

    ... myelodysplastic syndromes (MDS) Associated Drug(s):  ... period, and then resume prior medications. Patients with secondary acute myeloid leukemia arising from myeloproliferative disease, ...

    Clinical Trial last updated 06/06/2016 - 1:59pm.

  5. Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

    ... myelodysplastic syndromes (MDS) Associated Drug(s):  ... t (8;21), t(15;17), inv 16 without c-kit mutations). Secondary AML in remission AML in ≥ 2nd remission ALL in 1st ... t (8;21), t(15;17), inv 16 without c-kit mutations). Secondary AML in remission AML in ≥ 2nd remission ALL in 1st ...

    Clinical Trial last updated 04/29/2016 - 1:11pm.

  6. Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS

    ... stem cell transplantation in patients with high-risk MDS/AML. We hypothesize that adding valproic acid to azacitidine will improve ... In addition to assessing for 1 year survival, we will have secondary objectives of assessing progression-free survival, relapse, and ...

    Clinical Trial last updated 04/29/2016 - 12:35pm.

  7. Bone Marrow and Stem Cell Transplantation

    ... marrow failure disease like aplastic anemia , MDS or PNH , and your doctor thinks you may be a candidate for a ... , can also affect HSCT outcomes. People with secondary MDS , caused by a previous treatment for another disease or ...

    Page last updated 09/30/2014 - 11:47am.

  8. Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

    ... myelodysplastic syndromes (MDS) Phase:  ... (severe, recurrent, requiring medications, and felt to be secondary to the MPN) either after diagnosis or within 10 years before ...

    Clinical Trial last updated 05/02/2016 - 2:31pm.

  9. Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

    ... hemoglobinuria (PNH) or myelodysplastic syndrome (MDS) associated with cytopenias. Patients with BMFS have traditionally been ... primary endpoint of this study will be cGVHD at day 365. Secondary end points include transplant related mortality, engraftment, degree ...

    Clinical Trial last updated 04/28/2016 - 2:40pm.

  10. Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)

    ... myelodysplastic syndromes (MDS) Phase:  ... (severe, recurrent, requiring medications, and felt to be secondary to the MPN) either after diagnosis or within 10 years before ...

    Clinical Trial last updated 04/29/2016 - 9:59am.